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Abstract 
A psychiatric medication is a licensed psychoactive drug taken to exert an effect on the chemical makeup of the 
brain and nervous system. Thus, these medications are used to treat mental disorders. The aim of the current 
study was to determine the effect of anti-Psychotic drugs on lipid and prolactin level among Sudanese psychotic 
patients. This cross-sectional   study conducted in Altegani Almahi psychiatric Hospital, Khartoum state, Sudan, 
during the period of November 2015to March 2016. Seventy psychotic patients on first and second generation 
drugs were enrolled in this study. Any Patient had with chronic disease , receiving drugs or any that can affect  
lipid and hormones  level were excluded.  From each participant, 5 mL of blood sample was collected   in plain 
containers during the period of steady state then serum was separated and stored at −20°C  until  used for 
analysis of lipid  profile, which was measured using (Mindray instrument( BA-88Asemi-outo chemistry  
analyzer)  , and   the Concentration of prolactin level  was measured by ELISA techniques (state fax model 
3200) . Seventy Sudanese psychotics patients  using antipsychotic  drugs were enrolled in the study They were 
from both gender ; aged from 18-40 years . The Serum prolactin level  higher in male Patients used  
antipsychotic  rather than female (P≤0.05).  
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Also Total cholesterol (TC) and HDLwere significantly different in using different  types of drugs, however, 
triglyceride (TG) , and low-density lipoprotein (LDL-C) levels were not significantly different (P≥0.05).  
Antipsychotic drugs can cause significant abnormalities in lipid metabolism.and no difference regarding the 
gender .however the prolactin is significantly increased in male rather than female.  
Keywords: Anti-Psychotic drugs; Lipids; Prolactin ; Sudanese. 
1. Introduction  
Antipsychotic medications are an important component in the medical management of many psychotic 
conditions.Thus, these medications are used to treat mental disorders [1]. The  drug therapy in psychosis  inhibit 
most florid subjective and behavioral disturbances of psychosis and  restore the patient to as near normal to the 
society as possible by improving the quality of life and to decrease hospitalization [2]. The discovery of 
chlorpromazine and lithium in 1950‘s revolutionized the treatment of psychiatric disorders. The atypical 
antipsychotic agents (AAAs), which are sometimes referred to as second-generation antipsychotics (SGAs), are 
currently marketed in the United States for use in adults [3]. These AAAs include clozapine, risperidone, 
olanzapine, quetiapine, ziprasidone, aripiprazole, paliperidone, and asenapine .( risperidone, olanzapine mainly 
used in Sudan ) , These AAAs have established efficacy in the treatment of schizophrenia and bipolar mania in 
adults, and are utilized in the treatment of a variety of other illnesses as well [3].  At present, risperidone and 
aripiprazole are labeled by the FDA for use in children or adolescents for irritability associated with an autistic 
disorder for risperidone and  years for aripiprazole. Case reports have also described the use of clozapine in the 
treatment of youths with the treatment- resistant autistic disorder [4]. Risperidone of the AAAs,   has the most 
substantive amount of methodologically stringent evidence about its use in children and adolescents. In one of 
the largest methodologically rigorous studies involving the use of AAAs in children, risperidone was examined 
as a treatment for serious behavioral problems in children with autism ages 5-17. In this multi-site trial, a total of 
101 children with autism participated in a double-blind trial of risperidone, 0.5mg to 3.5mg per day versus 
placebo. The results from the initial study, a six-month continuation trial, and the blinded discontinuation trial 
found that risperidone treatment resulted in significant improvement in behavioral problems that persisted at six 
months and relapsed with medication discontinuation[5]. Olanzapine of the AAAs, olanzapine‟s receptor 
binding profile most closely matches that of clozapine. There is one double-blind, placebo-controlled study that 
has reported the short- term efficacy of olanzapine in the treatment of adolescents with schizophrenia. There is 
another double-blind, placebo-controlled study reporting the short-term efficacy of olanzapine in the treatment 
of adolescents with bipolar illness suffering from a manic or mixed episode. Another double-blind study, of 50 
total patients, comparing olanzapine, risperidone, and haloperidol in psychotic youths found olanzapine‟s 
effectiveness to be comparable to both haloperidol and risperidone [6]. Quetiapine One double-blind study 
found that in adolescents with mania, treatment with quetiapine plus divalproex sodium was associated with 
greater symptom reduction than treatment with quetiapine plus placebo. In an acute, double-blind, placebo-
controlled study, the efficacy of quetiapine has been reported in children and adolescents with bipolar mania [7]. 
Another placebo-controlled study has found that quetiapine has efficacy in adolescent schizophrenia. Open-label 
trials have noted potential benefit for aggression in conduct disorder, psychosis, mania, and tic disorders. Two 
reports in patients with PDD suggested sub-optimal effectiveness but another report suggested more positive 
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findings in this patient population [7]. The psychiatric medications are evolving into more novel methods of 
drug delivery. New technologies include transdermal, transmucosal, inhalation, and suppository supplements 
[8]. The Antipsychotics, which treat psychotic disorders such as schizophrenia and psychotic symptoms 
occurring in the context of other disorders such as mood disorders [9]. Certain antipsychotics may be associated 
with hyperlipidemias. These lipid abnormalities may increase the risk of coronary heart disease. Several 
retrospective reports   [10, 11] found elevations of lipids in patients who were taking newer antipsychotics. 
Early case reports focused on clozapine and found elevated levels of triglycerides but not elevated total 
cholesterol levels [10]. One study found that olanzapine was associated with higher triglyceride and cholesterol 
levels, compared with risperidone [10]. Patients with schizophrenia suffer from increased rates of multiple  
medical problems, due to their lifestyle (high smoking prevalence, high-fat diet), inherent neglect of personal 
care, and barriers to treatment of physical illness [12] A further important contributor to adverse health 
outcomes is the side effect profile of antipsychotic medications. Since the introduction of the second generation 
or atypical antipsychotics (AAP), treatment with first and second-generation antipsychotics can contribute to 
weight gain [13, 14]. Serum lipid levels may be influenced by multiple factors, including genetics, diet, weight 
gain, and exogenous agents like alcohol and medications. It seems that there is an  association between use of 
dibenzodiazepine-derived atypical antipsychotics (i.e., clozapine, olanzapine, quetiapine) and higher serum 
triglyceride levels [15]. Both risperidone and ziprasidone are non-dibenzodiazepine AAP, and a pear to have 
minimal effects on serum lipids [9, 16]] , The aim of this  study was to  assess   lipid profile  ( Cholesterol , 
Triglyceride ,  High-Density Lipoprotein (HDL), Low-Density Lipoprotein LDL) and prolactin level among 
Sudanese patients  were used anti-Psychotic drugs , referring to AlteganiAlmahipsychatric Hospital,  Khartoum 
state . 
2. Materials and Methods 
This is cross section and a hospital-based study conducted in Khartoum state at Altegani Almahi psychiatric 
Hospital during the period of November 2015to March 2016. Seventy psychotic patients on first and second 
generation drugs aged between 18-40 years were enrolled in this study. Any Patient had any chronic disease, 
receiving drugs that can affect lipids and hormones levels were excluded.  From each participant  5 mL of blood 
sample was collected   in plain containers during the period of steady state then serum was separated and stored 
at −20°C  until  used for analysis of lipid  profile, which was measured using (Mindray instrument( BA-
88Asemi-outo chemistry  analyzer)  , and   the Concentration of prolactin level  was measured by ELISA 
techniques (state fax model 3200) .  This study was approved by the faculty of medical laboratory sciences, Al 
neelain University, Department of clinical chemistry and informed consent was obtained from each participant 
before sample   collection. Data analysis was performed using SPSS(Statistical Package for the Social Science) 
Version19.0 statistical software. Dependent variable, percentage, mean, standard Deviation and range were 
calculated, P values <0.05 were considered as statistically significant. 
3. Results 
Total of 70 Sudanese psychotic Patients (20 patients   using haloperidol , 20 using olanzapine , 15  using 
risperidone  and 15 using quetiapine ) were enrolled to participate in this study, referring to Altegani 
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Almahipsychiatric Hospital,  Khartoum state, Sudan  Haloperidol was the most commonly prescribed 
antipsychotic followed by risperidone, quetiapine, and olanzapine  (Table 2). When haloperidol, risperidone 
quetiapine, and olanzapine were analyzed individually for metabolic changes at 12 weeks, all the three drugs 
caused a significant rise in body weight. Olanzapine caused a significant rise in serum cholesterol, serum HDL, 
and total lipid levels. Risperidone lead to statistically was not  significantly increased  serum triglycerides and 
serum HDL while haloperidol did not cause a significant change in any of these parameters. Regarding the 
gender , 39 (55.7%) of the patients were males and 31 (44.3%) were females, antipsychotics drugs  caused 
insignificant rise in serum lipid profile, however, the prolactin was significantly increased in male rather than 
female (P≤0.05) as shown in table I. Also Total cholesterol (TC) and HDL were significantly different in 
patients using different types of drugs, however, triglyceride (TG), and low-density lipoprotein (LDL-C) levels 
were not significantly different (P≥0.05) as shown in table II 
Table 1: Comparison of lipid profile and PRL between male and female using different types of antipsychotic 
drugs 
Parameters Male (M±STD) Female (M±STD) P. value  
TC (mg/dl) 156.00 ± 38.45 146.74 ±36.09 0.308** 
TG mg/dl 96.56 ± 31.54 90.29 ± 25.51 0.372** 
LDHmg/dl 98.05 ± 28.46 92.10 ± 28.28 0.386** 
HDL mg/dl 55.82 ± 13.82 51.19 ± 12.38 0.150** 
PRL  81.14 ± 63.66 22.10± 6.50 0.013** 
 **Not significant different at the 0.05 level. 
Table 2:  Comparison of mean (SD) of lipid profile between different types of antipsychotic drugs 
Variable Olanzapine Quetiapine Risperidone Hallo Peridone Total P.V 
TC 174.8(44.35) 140.6(26.88) 138.8(28.554) 147.4(34.416) 151.9(37.448) 0.009* 
TG 100.9 (35.68) 91.3(33.07) 91.3(33.07) 93.9(22.49) 93.8(29.00) 0.540** 
LDL 104.9(28.91) 87.0(17.81) 91.3(33.07) 95.3(29.57) 95.4(28.33) 0.275** 
HDL 61.5(16.34) 51.9(11.27) 52.1(12.13) 48.8(8.95) 53.8(13.31) 0.014* 
*Significant different at the 0.05 level. 
4. Discussion 
The present study shows that all antipsychotics together cause statistically significant increase in lipid profile 
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and prolactin. This finding is in agreement with studies done by TschonerA [15]. Moreno C [9], Gabriela B [16]  
they reported a significant increase in lipid profile . Our finding is in accordance with the study by Moreno C 
which shows that 3 months after starting treatment with second-generation antipsychotics more than 70% of 
patients had significant weight gain and incre prolactin level .Hampt D [17] and Pringsheim [17] . suggest that 
olanzapine is associated with greatest weight gain. The present study shows that all the antipsychotics taken 
together cause a statistically significant rise in all lipid parameters like serum total cholesterol,  serum HDL, and 
serum prolactin . These findings are in agree with Pringsheim, Moreno C10, Tschoner A9, Wirshing D.A.20, 
Osser and his colleagues [18] Meyer and his colleagues [19].. A study done by Moreno C10 shows that after 3 
months of therapy with second-generation antipsychotics more than 70% of patients had a significant rise in 
total cholesterol and low LDL which is in disagreeing with our study. Regarding atypical antipsychotics, both 
clozapine and olanzapine can increase blood lipid levels and this agree with Our study . Our finding is in 
accordance with an another retrospective analysis, comparing risk of diabetes during olanzapine  use with that 
during risperidone use, olanzapine was associated with an increased risk of developing diabetes compared to 
risperidone [20]. Abnormalities in glucose metabolism have been reported with other antipsychotics like 
chlorpromazine with increase prevalence of diabetes [21]. However all first generation antipsychotics do not 
cause abnormal glucose metabolism. In our study haloperidol has not caused any significant change in blood 
sugar level. 
5. Conclusion 
 Antipsychotics drugs can cause significant abnormalities in lipid metabolism regardless the gender .However 
the prolactin is significantly increased in male rather than female. So selection of antipsychotics, particularly the 
newer ones requires consideration of co morbidities like obesity, diabetes mellitus and dyslipidemias . 
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